loading
Schlusskurs vom Vortag:
$8.16
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$564.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
0.00
EPS:
-1.58
Netto-Cashflow:
$-27.38M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$8.345

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name
Firmenname
Regulus Therapeutics Inc
Name
Telefon
858-202-6300
Name
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Name
Mitarbeiter
34
Name
Twitter
@regulusrx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
RGLS's Discussions on Twitter

Vergleichen Sie RGLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGLS
Regulus Therapeutics Inc
0.00 564.26M 0 -30.04M -27.38M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.73 123.14B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
543.48 60.43B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.90 42.07B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.00 34.47B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.37 27.42B 3.81B -644.79M -669.77M -6.24

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-27 Hochstufung Wells Fargo Equal Weight → Overweight
2024-08-02 Eingeleitet Oppenheimer Outperform
2024-03-18 Eingeleitet Leerink Partners Outperform
2018-03-28 Eingeleitet B. Riley FBR, Inc. Neutral
2018-01-05 Eingeleitet Leerink Partners Outperform
2017-06-13 Bestätigt Chardan Capital Markets Buy
2017-03-06 Bestätigt Wedbush Outperform
2017-01-30 Herabstufung Needham Buy → Hold
2017-01-30 Herabstufung Wells Fargo Outperform → Market Perform
2016-12-07 Bestätigt Chardan Capital Markets Buy
2016-11-02 Bestätigt Needham Buy
2016-07-25 Bestätigt Chardan Capital Markets Buy
2016-06-28 Bestätigt Chardan Capital Markets Buy
2016-06-28 Bestätigt FBR Capital Outperform
2016-06-28 Bestätigt Needham Buy
2016-06-07 Bestätigt Chardan Capital Markets Buy
2016-04-13 Eingeleitet Chardan Capital Markets Buy
2015-12-04 Eingeleitet Wells Fargo Outperform
2015-06-09 Eingeleitet Guggenheim Buy
2015-04-21 Fortgesetzt FBR Capital Outperform
2014-11-24 Eingeleitet Deutsche Bank Buy
2014-08-07 Bestätigt FBR Capital Outperform
2013-08-14 Bestätigt Needham Buy
Alle ansehen

Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten

pulisher
08:51 AM

Is Regulus Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - Jammu Links News

08:51 AM
pulisher
02:42 AM

What analysts say about Regulus Therapeutics Inc. stockTremendous financial leverage - Jammu Links News

02:42 AM
pulisher
01:36 AM

Will Regulus Therapeutics Inc. stock split in the near futureHigh Potential Shares - Newser

01:36 AM
pulisher
Jul 15, 2025

Why Regulus Therapeutics Inc. stock attracts strong analyst attentionFree Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Regulus Therapeutics Inc. stock performs during market volatilityAlpha Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Regulus Therapeutics Inc. stock price move sharplyHigh Reward Swing Trades - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Average Rating of “Hold” from Analysts - Defense World

Jul 14, 2025
pulisher
Jul 05, 2025

Oppenheimer & Co. Inc. Takes Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World

Jul 05, 2025
pulisher
Jul 02, 2025

Regulus Therapeutics to be Acquired by Novartis - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha

Jul 02, 2025
pulisher
Jun 30, 2025

Regulus Investor Drops Suit After $1.7 Billion Novartis Sale - Bloomberg Law News

Jun 30, 2025
pulisher
Jun 28, 2025

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion - Yahoo Finance

Jun 28, 2025
pulisher
Jun 26, 2025

Novartis concludes acquisition of Regulus Therapeutics - Medical Dialogues

Jun 26, 2025
pulisher
Jun 25, 2025

Novartis Completes Tender Offer for Regulus Therapeutics - PharmiWeb.com

Jun 25, 2025
pulisher
Jun 25, 2025

Novartis (NVS) Concludes Acquisition Offer for Regulus Therapeutics | NVS Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Novartis completes acquisition of Regulus Therapeutics - MarketScreener

Jun 25, 2025
pulisher
Jun 23, 2025

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer - The Manila Times

Jun 23, 2025
pulisher
Jun 22, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $8.50 Consensus Price Target from Analysts - Defense World

Jun 22, 2025
pulisher
Jun 18, 2025

Biopharma Deal Premiums Paint Picture of Cutthroat Negotiations - BioSpace

Jun 18, 2025
pulisher
Jun 05, 2025

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 01, 2025

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.

Jun 01, 2025
pulisher
May 28, 2025

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma

May 28, 2025
pulisher
May 28, 2025

Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues

May 28, 2025
pulisher
May 27, 2025

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News

May 27, 2025
pulisher
May 27, 2025

Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times

May 27, 2025
pulisher
May 27, 2025

Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener

May 27, 2025
pulisher
May 25, 2025

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha

May 25, 2025
pulisher
May 16, 2025

With IPO markets dead, biotechs search for M&A - Axios

May 16, 2025
pulisher
May 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView

May 15, 2025
pulisher
May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView

May 15, 2025
pulisher
May 15, 2025

Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media

May 15, 2025
pulisher
May 15, 2025

Unlocking Profits with the Magical Signal How the Bullish Signal Transformed Regulus Therapeutics - AInvest

May 15, 2025
pulisher
May 14, 2025

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail

May 14, 2025
pulisher
May 14, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World

May 14, 2025
pulisher
May 12, 2025

Novartis to Acquire Regulus Therapeutics - San Diego Business Journal

May 12, 2025
pulisher
May 10, 2025

Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World

May 10, 2025
pulisher
May 09, 2025

Regulus Therapeutics’ Q1 2025 Results Signal a New Era for Kidney Disease Treatment and Investor Value - AInvest

May 09, 2025
pulisher
May 08, 2025

Regulus: Q1 Earnings Snapshot - Norwalk Hour

May 08, 2025
pulisher
May 08, 2025

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World

May 07, 2025
pulisher
May 06, 2025

Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN

May 06, 2025
pulisher
May 06, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com

May 06, 2025
pulisher
May 05, 2025

What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World

May 05, 2025
pulisher
May 04, 2025

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire

May 04, 2025
pulisher
May 04, 2025

Regulus Therapeutics' $1.7 Billion Deal with Novartis Faces Scrutiny: Is the Price Fair? - AInvest

May 04, 2025

Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.19
price up icon 0.86%
$35.45
price up icon 0.37%
$104.57
price up icon 0.51%
$27.95
price up icon 1.07%
$110.73
price down icon 0.10%
biotechnology ONC
$298.88
price up icon 3.15%
Kapitalisierung:     |  Volumen (24h):